

S8 Table. Efficacy parameters of racemic praziquantel (PZQ) treatment on infected preschool-aged children (PSAC) and school-aged children (SAC), and the effect of the different brands of PZQ available. The brands, when named, are listed in subscript; BILT: Biltricide, DIS: Distocide. The superscript descriptions show the additional information of the study; (a): Heavy egg load, (b): Moderate egg load, (c): Light egg load.

Drug Administered	PZQ Dose (mg/kg)	N	Egg Reduction Rate (%)	Cure Rate (%)
PZQ ^[1-3]	20			
<i>PSAC (haematobium)</i>		39	98.6	88.2
<i>PSAC (mansoni)</i>		32	90.8	65.5
<i>SAC (haematobium)</i>		45	97.5	54.6
<i>SAC (mansoni)</i>		47	84.2	30.4
<i>SAC (haematobium)</i>		11	100	100
<i>SAC_(BILT) ^(a) (mansoni)</i>		20	96.4	30.0
<i>SAC_(BILT) ^(b) (mansoni)</i>		39	86.2	42.4
<i>SAC_(BILT) ^(c) (mansoni)</i>		33	72.7	66.7
<i>SAC_(DIS) ^(a) (mansoni)</i>		25	98.0	47.1
<i>SAC_(DIS) ^(b) (mansoni)</i>		65	94.0	38.7
<i>SAC_(DIS) ^(c) (mansoni)</i>		35	86.1	57.1
PZQ ^[1-4]	40			
<i>PSAC (haematobium)</i>		43	97.1	77.5
<i>PSAC (mansoni)</i>		29	95.3	74.1
<i>SAC (haematobium)</i>		46	98.8	72.5
<i>SAC (mansoni)</i>		46	98.3	68.9
<i>SAC (haematobium)</i>		13	100	100
<i>SAC (mansoni)</i>		30	82.0	70.0
<i>SAC_(BILT) ^(a) (mansoni)</i>		30	96.5	73.3
<i>SAC_(BILT) ^(b) (mansoni)</i>		26	85.4	52.0
<i>SAC_(BILT) ^(c) (mansoni)</i>		24	79.5	66.7
<i>SAC_(DIS) ^(a) (mansoni)</i>		30	99.9	90
<i>SAC_(DIS) ^(b) (mansoni)</i>		15	93.4	46.7
<i>SAC_(DIS) ^(c) (mansoni)</i>		24	90.3	70.9
PZQ ^[1, 2, 4]	60			
<i>PSAC (haematobium)</i>		41	96.3	67.6
<i>PSAC (mansoni)</i>		33	97.6	78.1
<i>SAC (haematobium)</i>		44	97.5	63.4
<i>SAC (mansoni)</i>		42	99.1	82.9
<i>SAC (haematobium)</i>		11	99.4	90.9
<i>SAC (mansoni)</i>		28	91	82

References

1. Kovac J, Meister I, Neodo A, Panic G, Coulibaly JT, Falcoz C, et al. Pharmacokinetics of Praziquantel in Schistosoma mansoni- and Schistosoma haematobium-Infected School- and Preschool-Aged Children. *Antimicrobial agents and chemotherapy*. 2018;62(8). doi: 10.1128/AAC.02253-17;e02253-17. PubMed PMID: WOS:000440008400078.
2. Kovac J, Panic G, Neodo A, Meister I, Coulibaly JT, Schulz JD, et al. Evaluation of a novel micro-sampling device, Mitra (TM), in comparison to dried blood spots, for analysis of praziquantel in Schistosoma haematobium-infected children in rural Cote d'Ivoire. *Journal of Pharmaceutical and Biomedical Analysis*. 2018;151:339-46. doi: 10.1016/j.jpba.2018.01.030. PubMed PMID: WOS:000426025700041.
3. Metwally A, Bennett J, Botros S, Ebeid F, el attar Gel D. Impact of drug dosage and brand on bioavailability and efficacy of praziquantel. *Pharmacological research*. 1995;31(1):53-9. Epub 1995/01/01. PubMed PMID: 7784306.
4. Bustinduy AL, Waterhouse D, de Sousa-Figueiredo JC, Roberts SA, Atuhaire A, Van Dam GJ, et al. Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy. *mBio*. 2016;7(4). Epub 2016/08/11. doi: 10.1128/mBio.00227-16. PubMed PMID: 27507822; PubMed Central PMCID: PMC4992966.